Trial tests precision dosing for patients who metabolize tamoxifen poorly

By Tahani Elghazaly
Published October 12, 2026

Latest news on WhatsApp أجدد الأخبار على واتساب

A long-standing problem with tamoxifen is that two patients taking the same dose can end up with very different levels of the drug’s active metabolite. A German randomized trial suggests that directly adding small amounts of (Z)-endoxifen could offer a practical way to correct that imbalance in selected breast cancer patients.

Tamoxifen must be metabolized into endoxifen before it can deliver much of its anti-estrogen activity. Genetic variation in the CYP2D6 enzyme can weaken that conversion, leaving some women with substantially lower active-drug concentrations despite standard treatment.

The TAMENDOX trial enrolled 235 women with early-stage, hormone receptor-positive breast cancer across 38 German centres. All received the standard 20-mg daily tamoxifen dose, while selected patients were assigned low-dose endoxifen — either 1.5 mg or 3 mg per day — according to their CYP2D6 status or measured endoxifen concentration.

The intervention largely corrected the pharmacological shortfall. Among poor metabolizers receiving 3 mg of endoxifen, 92.3% reached the study’s target blood concentration, as did every participant who entered the trial with very low endoxifen levels. The lower 1.5-mg dose brought 88% of intermediate metabolizers and 95% of patients with moderately low baseline levels above the same threshold.

Safety findings were broadly comparable during the six-week treatment period. Grade 3 adverse events occurred in 7.5% of patients receiving supplemental endoxifen and 5.2% of those receiving placebo.

The strategy may be particularly relevant for premenopausal women, who can have fewer endocrine-treatment alternatives than postmenopausal patients. Researchers at the Bosch Health Campus have described the approach as a potential step toward tailoring tamoxifen therapy to an individual patient’s metabolism rather than relying on a uniform dose for everyone.

What the trial did not establish is equally important. It was designed to test drug concentrations and safety, not whether supplemental endoxifen lowers recurrence rates or improves survival. Larger and longer studies would be needed before the approach could become routine clinical practice.

The study was published in Clinical Cancer Research in December 2025, so its findings should be presented as prior clinical research rather than as a newly released 2026 discovery.